Meraz, Ismail M. http://orcid.org/0000-0001-9109-5196
Majidi, Mourad
Fang, Bingliang
Meng, Feng
Gao, Lihui
Shao, RuPing
Song, Renduo
Li, Feng
Lissanu, Yonathan
Chen, Huiqin
Ha, Min Jin
Wang, Qi
Wang, Jing http://orcid.org/0000-0002-5398-0802
Shpall, Elizabeth
Jung, Sung Yun http://orcid.org/0000-0003-1521-7977
Haderk, Franziska
Gui, Philippe
Riess, Jonathan Wesley
Olivas, Victor
Bivona, Trever G. http://orcid.org/0000-0001-5734-4128
Roth, Jack A. http://orcid.org/0000-0002-8955-1313
Article History
Received: 11 August 2022
Accepted: 1 May 2023
First Online: 11 May 2023
Change Date: 6 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-023-04979-9
Competing interests
: Jack A. Roth reports receiving a commercial research grant from The University of Texas MD Anderson Cancer Center, sponsored research agreement from Genprex, Inc, has ownership interest (including stock, patents, etc.) in Genprex, Inc., and is a consultant/advisory board member for Genprex, Inc. Trever G. Bivona is an advisor to Array/Pfizer, Revolution Medicines, Springworks, Jazz Pharmaceuticals, Relay Therapeutics, Rain Therapeutics, Engine Biosciences, and receives research funding from Novartis, Strategia, Kinnate, and Revolution Medicines. Jonathan Wesley Riess is an advisor to Blueprint, Beigene, Daiichi Sankyo, EMD Serono, Janssen, Turning Point, Regeneron, Sanofi Aventis and a consultant to Blueprint, Novartis, Boehringer Ingelheim. He also receives research funding from Merck, Novartis, Spectrum, Revolution Medicine, AstraZeneca. Elizabeth Shpall is involved in consulting/Scientific advisory board/Speaking in Adaptimmune, Navan, Celaid Therapeutics, Zelluna Immunotherapy, FibroBiologics and Axio. She has also license agreement with Takeda, Affimed and Syena. The other authors disclosed no potential conflicts of interest or competing interests.